What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @DrMiniDey: Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs con

      Mrinalini Dey DrMiniDey

      4 years ago
      Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21 •No incr. risk of AEs in autoimmune disease vs controls •Minimal impact of vaccines on disease activity @RheumNow https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX
      RT @drdavidliew: FAERS data of potential rheumatic irAEs:
      'Arthralgia' consistently top of the list - readily underrepor

      David Liew drdavidliew

      4 years ago
      FAERS data of potential rheumatic irAEs: 'Arthralgia' consistently top of the list - readily underreported, causality unclear, hard to know what it is This is why there's only a limited amount we can learn about rheumatic irAEs without dedicated study #ACR21 ABST0438 @RheumNow https://t.co/8HElxUZS8n
      RT @KDAO2011: #ACR21 #GreatDebate: Dr. Rovin argues for VCS add to MMF b/c:
      👉fewer side effects than legacy CNI
      👉e

      TheDaoIndex KDAO2011

      4 years ago
      #ACR21 #GreatDebate: Dr. Rovin argues for VCS add to MMF b/c: 👉fewer side effects than legacy CNI 👉elevated in creatinine related hemodynamic reversible effect 👉did increase BP (but controllable) @rheumnow (2/2) https://t.co/mmWp0sBveT
      RT @KDAO2011: #ACR21 #GreatDebate: Dr. Rovin argues for VCS add to MMF b/c:
      👉improvement in complete renal response
      ð

      TheDaoIndex KDAO2011

      4 years ago
      #ACR21 #GreatDebate: Dr. Rovin argues for VCS add to MMF b/c: 👉improvement in complete renal response 👉rapid proteinuria resolution (in days!) 👉protect podocytes➡️protecting glomeruli➡️protect GFR 👉effective in black patients. 👉rapid steroid taper @rheumnow (1/2)
      RT @RHEUMarampa: Dr Rovin: How do calcineurin inhibitors protect podoctyes?
      👉by protecting synaptopodin (critical for

      sheila RHEUMarampa

      4 years ago
      Dr Rovin: How do calcineurin inhibitors protect podoctyes? 👉by protecting synaptopodin (critical for stabilizing the actin cytoskeleton) 👉also by reducing podocyte apoptosis @RheumNow #ACR21 #lupus #MedTwitter https://t.co/QZTwiT5Hd7
      RT @synovialjoints: There remains a need to increase knowledge and awareness of #axialspondyloarthritis in this US stud

      Dr. Antoni Chan synovialjoints

      4 years ago
      There remains a need to increase knowledge and awareness of #axialspondyloarthritis in this US study of nearly 200 primary care physicians, less than half of the time were IBP symptoms, psoriasis, HLA-B27, CRP or MRI checked @RheumNow, #ACR21 Abst#0370 https://t.co/6Uyy45OEYZ
      RT @ericdeinmd: Personalize decision points in belimumab vs voclosporin @jhrheumatology Dr. Petri
      ▶️ What is the out

      Eric Dein ericdeinmd

      4 years ago
      Personalize decision points in belimumab vs voclosporin @jhrheumatology Dr. Petri ▶️ What is the outcome you are most interested in? GFR? ▶️ Is there extra-renal lupus ▶️ Infection risk ⭐️Ultimately, need biomarkers to know who will respond the best @Rheumnow #ACR21 Great Debate
      RT @DrPetryna: Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry.

      Olga Petryna DrPetryna

      4 years ago
      Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss11.4%. ⬇️ breastfeeding rate at 33.7% https://t.co/plF8fykCKT
      RT @RHEUMarampa: KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study

      sheila RHEUMarampa

      4 years ago
      KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
      RT @uptoTate: RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a g

      Dr. Rachel Tate uptoTate

      4 years ago
      RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a good start, but offers questions regarding dosing of CAN in this patient population. Abs 0192 #ACR21 #RheumNow @RheumNow https://t.co/46o7AnUVj2 https://t.co/7oAPovbukl
      RT @synovialjoints: Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain

      Dr. Antoni Chan synovialjoints

      4 years ago
      Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain intensity was associated with working life impairment, spinal stiffness, education, gender, depression, anxiety and sleep @RheumNow, #ACR21 and Abst#0360 https://t.co/xEVI4L0Chw
      RT @MeralElRamahiMD: #ACR21 Abst#0289: Predictive score for preclinical RA-ILD based on 4 identified RF:
      ⭐︎ ⚦ sex

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0289: Predictive score for preclinical RA-ILD based on 4 identified RF: ⭐︎ ⚦ sex (OR 3.9) ⭐︎ MUC5B T-risk allele (OR 3.7) ⭐︎ mean DAS-28 (OR 2.0) ⭐︎ older age at RA onset (1.1) Obtain HRCT if w/ above (Se ~87%)! #ACRBest @Rheumnow https://t.co/KKRkQVY2pf https://t.co/wifiTi6vPq
      RT @uptoTate: RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigato

      Dr. Rachel Tate uptoTate

      4 years ago

      RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigators observed a trend toward updosing over standard dosing. Abs 0191 #ACR21 #RheumNow @RheumNow https://t.co/ik6dAEZjFf https://t.co/arqSEzuC6Q

      RT @doctorRBC: Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy.
      Dr. Petri argues Belimumab has les

      Robert B Chao, MD doctorRBC

      4 years ago
      Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy. Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions. What would you choose? #ACR21 #ACRBest @RheumNow https://t.co/FywUp3zCj2
      RT @RichardPAConway: Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆ï¸

      Richard Conway RichardPAConway

      4 years ago
      Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×